ALUPENT
LOE ApproachingNDAINHALATIONAEROSOL, METEREDPriority Review
Approved
Jul 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is a metered-dose inhaled aerosol small molecule approved in 1973 for respiratory indications. The specific mechanism of action and therapeutic indication are not detailed in available data, but the inhalation route and aerosol formulation suggest use in obstructive airway disease. This is a legacy product with over 50 years of market history.
LOE Approaching
This product is in late lifecycle with approaching loss of exclusivity, suggesting a lean brand team focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring activity; roles on ALUPENT are likely stable, mature positions focused on defending market share rather than growth. This product offers limited career momentum and is best suited for professionals seeking a stable tenure rather than advancement.
Field Sales RepresentativeBrand Manager
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.